Vaxess Technologies, Inc. was launched by a team of Harvard graduate students developing a suite of vaccines on the MIMIX sustained dermal delivery platform combineing high temperature stability, improved efficacy, and simplified delivery to improve global vaccine access. Based in technology developed at Tufts, the effort has been to use a silk-derived protein to make make vaccines that are both temperature stable and soluble - effectively removing the need for refrigeration and eliminating the need for cold-chain transport. This stabilization of vaccines such that they can be stored and shipped without refrigeration also permits use of a novel sustained release micro-needle for improved vaccine delivery. The potential impact of the Vaxess effort overall not only lowers the cost of vaccine distribution, but also increase access to life-saving products.